日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

一项针对晚期癌症患者的I/II期临床试验，研究口服SRA737（一种Chk1抑制剂）联合低剂量吉西他滨的疗效。

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-2074
Jones, Robert; Plummer, Ruth; Moreno, Victor; Carter, Louise; Roda, Desamparados; Garralda, Elena; Kristeleit, Rebecca; Sarker, Debashis; Arkenau, Tobias; Roxburgh, Patricia; Walter, Harriet S; Blagden, Sarah; Anthoney, Alan; Klencke, Barbara J; Kowalski, Mark M; Banerji, Udai
肿瘤
SRA
肿瘤免疫
发表日期：2023
文献求助 收藏

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

一项针对EGFR突变、未接受过酪氨酸激酶抑制剂治疗的转移性非小细胞肺癌的厄洛替尼和莫美替尼的1b期研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-021-04369-0
Padda, Sukhmani K; Reckamp, Karen L; Koczywas, Marianna; Neal, Joel W; Kawashima, Jun; Kong, Shengchun; Huang, Daniel B; Kowalski, Mark; Wakelee, Heather A
肺癌
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
细胞生物学
发表日期：2022
文献求助 收藏

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

ACVR1/JAK1/JAK2抑制剂momelotinib在骨髓纤维化II期临床试验中逆转输血依赖并抑制铁调素。

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2020002662
Oh, Stephen T; Talpaz, Moshe; Gerds, Aaron T; Gupta, Vikas; Verstovsek, Srdan; Mesa, Ruben; Miller, Carole B; Rivera, Candido E; Fleischman, Angela G; Goel, Swati; Heaney, Mark L; O'Connell, Casey; Arcasoy, Murat O; Zhang, Yafeng; Kawashima, Jun; Ganz, Tomas; Kowalski, Mark; Brachmann, Carrie Baker
JAK/STAT
JAK1
JAK2
发表日期：2020
文献求助 收藏

Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial

使用TKM-130803治疗埃博拉病毒病的实验性研究：一项单臂II期临床试验

期刊:PLoS Medicine
影响因子:9.9
doi:10.1371/journal.pmed.1001997
Dunning, Jake; Sahr, Foday; Rojek, Amanda; Gannon, Fiona; Carson, Gail; Idriss, Baimba; Massaquoi, Thomas; Gandi, Regina; Joseph, Sebatu; Osman, Hassan K; Brooks, Timothy J G; Simpson, Andrew J H; Goodfellow, Ian; Thorne, Lucy; Arias, Armando; Merson, Laura; Castle, Lyndsey; Howell-Jones, Rebecca; Pardinaz-Solis, Raul; Hope-Gill, Benjamin; Ferri, Mauricio; Grove, Jennifer; Kowalski, Mark; Stepniewska, Kasia; Lang, Trudie; Whitehead, John; Olliaro, Piero; Samai, Mohammed; Horby, Peter W
微生物学
发表日期：2016
文献求助 收藏

IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression

IL-10 通过调节 IFN 调节因子 8 的表达来控制炎症反应中胱抑素 C 的合成和血液浓度

期刊:Journal of Immunology
影响因子:3.6
doi:10.4049/jimmunol.1001934
Yuekang Xu, Petra Schnorrer, Anna Proietto, Greg Kowalski, Mark A Febbraio, Hans Acha-Orbea, Ross A Dickins, Jose A Villadangos
信号转导
发表日期：2011
文献求助 收藏

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

一项 I 期研究，旨在评估膀胱内注射靶向 EpCAM 的免疫毒素治疗 BCG 难治性或 BCG 不耐受患者的非肌层浸润性膀胱癌的疗效

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S14071
Kowalski Mark, Entwistle Joycelyn, Cizeau Jeannick, Niforos Demi, Loewen Shauna, Chapman Wendy, MacDonald Glen C
免疫/内分泌
发表日期：2010
文献求助 收藏

A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

VB4-845 的 I 期临床研究：每周对头颈部鳞状细胞癌患者进行瘤内注射抗 EpCAM 重组融合蛋白

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/dddt.s3442
MacDonald Glen C, Rasamoelisolo Michèle, Entwistle Joycelyn, Cizeau Jeannick, Bosc Denis, Cuthbert Wendy, Kowalski Mark, Spearman Maureen, Glover Nick
细胞生物学
发表日期：2009
文献求助 收藏